Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human
| العنوان: | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
|---|---|
| المؤلفون: | Laurence A. Mulard, Barel Louis-Antoine |
| المساهمون: | Chimie des Biomolécules - Chemistry of Biomolecules, Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Université Paris Descartes - Paris 5 (UPD5), This work has received funding from the Institut Pasteur (GPF project FlexBiVac, Vaccinology Program), the French National Research Agency (grant # ANR-15-CE07-0019-01). Louis Antoine Barel (L.A.B) is the recipient of an ANR PhD fellowship (contract Nb ANR-15-CE07-0019-01), he is affiliated to the Médicament, Toxicologie, Chimie, Imageries (MTCI) doctoral school., ANR-15-CE07-0019,CarbUniVax,Synergie entre synthèse chimique et ingénierie d'enzymes pour le développement de vaccins glycoconjugués à large spectre(2015), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS) |
| المصدر: | Human Vaccines & Immunotherapeutics Human Vaccines & Immunotherapeutics, Taylor & Francis, 2019, 15 (6), pp.1338-1356. ⟨10.1080/21645515.2019.1606972⟩ Human Vaccines & Immunotherapeutics, 2019, 15 (6), pp.1338-1356. ⟨10.1080/21645515.2019.1606972⟩ |
| بيانات النشر: | HAL CCSD, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | MESH: Vaccines, Conjugate, Glycoconjugate, Review, Disease, medicine.disease_cause, MESH: Shigella, 0302 clinical medicine, Shigella Vaccines, vaccine, MESH: Antibodies, Bacterial, Immunology and Allergy, Shigella, 030212 general & internal medicine, glycoconjugate, chemistry.chemical_classification, Clinical Trials as Topic, glycan, lipopolysaccharide, MESH: Shigella Vaccines, Dysentery, clinical trial, Antibodies, Bacterial, 3. Good health, carbohydrate antigen, MESH: Carbohydrates, O-acetylation, MESH: Clinical Trials as Topic, MESH: Dysentery, Bacillary, 030231 tropical medicine, Immunology, Carbohydrates, 03 medical and health sciences, Antibiotic resistance, Immune system, Antigen, Conjugate vaccine, medicine, Humans, oligosaccharide, MESH: Glycoconjugates, Dysentery, Bacillary, Pharmacology, Antigens, Bacterial, Vaccines, Conjugate, MESH: Humans, business.industry, medicine.disease, chemistry, Bioconjugate, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, business, Glycoconjugates, MESH: Antigens, Bacterial |
| الوصف: | International audience; Shigella are gram-negative bacteria that cause severe diarrhea and dysentery, with a high level of antimicrobial resistance. Disease-induced protection against reinfection in Shigella-endemic areas provides convincing evidence on the feasibility of a vaccine and on the importance of Shigella lipopolysaccharides as targets of the host humoral protective immune response against disease. This article provides an overview of the original and current strategies toward the development of a Shigella glycan-protein conjugate vaccine that would cover the most commonly detected strains. Going beyond pioneering “lattice”-type polysaccharide-protein conjugates, progress, and challenges are addressed with focus on promising alternatives, which have reached phases I and II clinical trial. Glycoengineered bioconjugates and “sun”-type conjugates featuring well-defined synthetic carbohydrate antigens are discussed with insights on the molecular parameters governing the rational design of a cost-effective glycoconjugate vaccine efficacious in preventing diseases caused by Shigella in the most at risk populations, young children living in endemic areas. |
| اللغة: | English |
| تدمد: | 2164-5515 2164-554X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a81b8eaa9aac0db10e764a8d40a56c https://hal.archives-ouvertes.fr/hal-02916015 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....d8a81b8eaa9aac0db10e764a8d40a56c |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 21645515 2164554X |
|---|